Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Gynecology | Oncology | Pharmacy | Conference News

Back to Journal Articles

ESMO: Conjugate Ups Survival in Advanced Breast Cancer

Last Updated: October 02, 2012.

 

Antibody-drug conjugate improves survival for patients with HER2-positive cancers

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Patients with advanced breast cancer positive for human epidermal growth factor receptor 2 have improved survival when treated with the antibody-drug conjugate trastuzumab emtansine, compared with lapatinib plus capecitabine, according to a study published online Oct. 1 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the European Society for Medical Oncology, held from Sept. 28 to Oct. 2 in Vienna.

TUESDAY, Oct. 2 (HealthDay News) -- Patients with advanced breast cancer positive for human epidermal growth factor receptor 2 (HER2) have improved survival when treated with the antibody-drug conjugate trastuzumab emtansine (T-DM1), compared with lapatinib plus capecitabine, according to a study published online Oct. 1 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the European Society for Medical Oncology, held from Sept. 28 to Oct. 2 in Vienna.

Sunil Verma, M.D., from the Sunnybrook Odette Cancer Centre in Toronto, and colleagues randomly assigned 991 patients with advanced HER2-positive breast cancer to T-DM1 or lapatinib plus capecitabine. Patients had previously been treated with trastuzumab and a taxane.

The researchers found that the T-DM1 group had significantly longer median progression-free survival (9.6 versus 6.4 months; hazard ratio for progression or death from any cause, 0.65) and significantly longer median overall survival (30.9 versus 25.1 months; hazard ratio of death from any cause, 0.68). The T-DM1 group had lower rates of grade 3 or 4 adverse events (41 versus 57 percent). This group also had a significantly higher objective response rate and a longer median duration of response.

"In conclusion, our study shows that T-DM1 has therapeutic potential, across a heterogeneous population of patients, for the treatment of advanced, HER2-positive breast cancer that has progressed during or after treatment with trastuzumab and a taxane," Verma and colleagues conclude.

The study was funded by Hoffmann-La Roche/Genentech, the manufacturer of trastuzumab emtansine; several authors disclosed financial ties to pharmaceutical companies, including Hoffmann-La Roche/Genentech.

Abstract
Full Text
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Many Juvenile Detainees Have Psychiatric Disorders Later On Next: Study Probes How Some HIV Patients Resist AIDS

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.